Search results
Yusuf Khwaja Hamied (born 25 July 1936) is an Indian scientist, billionaire businessman and the chairman of Cipla, a generic pharmaceuticals company founded by his father Khwaja Abdul Hamied in 1935. He is also an elected fellow of the Indian National Science Academy .
Yusuf Hamied is the non-executive chairman of Mumbai-based generics maker Cipla. Cipla was founded in 1935 by his father Khwaja Abdul Hamied, a disciple of Mahatma Gandhi.
Oct 11, 2023 · Yusuf Hamied is the non-executive chairman of $2.8 billion (revenue) generics maker Cipla. The company was founded in 1935 by his father Khwaja Abdul Hamied, a disciple of Mahatma...
Jan 25, 2016 · In 1992, the editor of The Times of India telephoned one of Mumbai’s most prominent businessmen—Yusuf K Hamied. The editor asked Yusuf, “as a Muslim leader”, his opinion on communal riots ...
Jan 28, 2022 · Yusuf Hamied joined the family business in 1960 and became prominent for his role in defying Western multinational pharmaceutical companies in order to provide generic AIDS treatments and...
Jul 15, 2019 · Dr. Yusuf Hamied of Cipla was a prolific reader of medical journals, with an annual subscription budget that topped $150,000 (Rs1 crore at current rates). One day in 1986, he was introduced to...
Yusuf Hamied is Chairman, Cipla, a leading pharmaceutical company established in India in 1935. He graduated with honours from Cambridge University in 1957 and continued to a PhD in 1960 under the tutelage of the Nobel Laureate, Alexander Todd.
Yusuf Hamied became a global celebrity for his role in defying Western multinational pharmaceutical companies in order to provide generic AIDS treatments and other drugs to treat poor people in the developing world.
Yusuf Hamied, 84, chairman of Cipla, recalls the time when he was called a pirate. That was in 2001, and Hamied’s company was offering to sell for $1 a day, or around $350 a year, the then...
Nov 18, 2015 · Today, as Non-Executive Chairman of the company now known as CIPLA, Yusuf Hamied keeps a close watch on his family's generic drugs giant, which turns over US$2 billion annually and employs around 26 000 people in India and several other locations worldwide.
